CN1263720C - 三苯基烯烃衍生物和它们作为选择性雌激素受体调制剂的用途 - Google Patents

三苯基烯烃衍生物和它们作为选择性雌激素受体调制剂的用途 Download PDF

Info

Publication number
CN1263720C
CN1263720C CNB008156255A CN00815625A CN1263720C CN 1263720 C CN1263720 C CN 1263720C CN B008156255 A CNB008156255 A CN B008156255A CN 00815625 A CN00815625 A CN 00815625A CN 1263720 C CN1263720 C CN 1263720C
Authority
CN
China
Prior art keywords
phenyl
chloro
nmr
cdcl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB008156255A
Other languages
English (en)
Chinese (zh)
Other versions
CN1399622A (zh
Inventor
M·-L·瑟德瓦尔
A·卡拉普达斯
L·坎加斯
R·拉明陶斯塔
P·海尔科宁
K·韦内宁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valorum Multi Pharmaceutical Co Ltd
Original Assignee
Hormos Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hormos Medical Ltd filed Critical Hormos Medical Ltd
Publication of CN1399622A publication Critical patent/CN1399622A/zh
Application granted granted Critical
Publication of CN1263720C publication Critical patent/CN1263720C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/09—Diamines
    • C07C211/10—Diaminoethanes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/16—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic the nitrogen atom of the amino group being further bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/20—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/11—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/12—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/225—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Steroid Compounds (AREA)
CNB008156255A 1999-11-16 2000-11-01 三苯基烯烃衍生物和它们作为选择性雌激素受体调制剂的用途 Expired - Lifetime CN1263720C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16582899P 1999-11-16 1999-11-16
US60/165,828 1999-11-16

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNB200610084709XA Division CN100441556C (zh) 1999-11-16 2000-11-01 三苯基烯烃衍生物和它们作为选择性雌激素受体调制剂的用途

Publications (2)

Publication Number Publication Date
CN1399622A CN1399622A (zh) 2003-02-26
CN1263720C true CN1263720C (zh) 2006-07-12

Family

ID=22600649

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB008156255A Expired - Lifetime CN1263720C (zh) 1999-11-16 2000-11-01 三苯基烯烃衍生物和它们作为选择性雌激素受体调制剂的用途
CNB200610084709XA Expired - Lifetime CN100441556C (zh) 1999-11-16 2000-11-01 三苯基烯烃衍生物和它们作为选择性雌激素受体调制剂的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB200610084709XA Expired - Lifetime CN100441556C (zh) 1999-11-16 2000-11-01 三苯基烯烃衍生物和它们作为选择性雌激素受体调制剂的用途

Country Status (29)

Country Link
US (2) US6576645B1 (https=)
EP (1) EP1235776B1 (https=)
JP (1) JP4202647B2 (https=)
KR (2) KR20080015924A (https=)
CN (2) CN1263720C (https=)
AT (1) ATE317378T1 (https=)
AU (1) AU778296B2 (https=)
BG (1) BG65853B1 (https=)
BR (1) BRPI0014901B8 (https=)
CA (1) CA2390116C (https=)
CZ (1) CZ304738B6 (https=)
DE (1) DE60025938T2 (https=)
DK (1) DK1235776T3 (https=)
EE (1) EE05126B1 (https=)
ES (1) ES2253268T3 (https=)
HR (1) HRP20020223C1 (https=)
HU (1) HU228512B1 (https=)
IL (2) IL148198A0 (https=)
MX (1) MXPA02002154A (https=)
NO (2) NO328010B1 (https=)
NZ (1) NZ518542A (https=)
PL (1) PL201512B1 (https=)
PT (1) PT1235776E (https=)
RU (1) RU2247715C2 (https=)
SK (1) SK287752B6 (https=)
TW (1) TW593256B (https=)
UA (1) UA76409C2 (https=)
WO (1) WO2001036360A1 (https=)
ZA (1) ZA200201433B (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW593256B (en) * 1999-11-16 2004-06-21 Hormos Medical Oy Ltd Triphenylalkene derivatives and their use as selective estrogen receptor modulators
FI111710B (fi) 2001-05-04 2003-09-15 Hormos Medical Oy Ltd Menetelmä terapeuttisesti aktiivisen yhdisteen valmistamiseksi
US20040248989A1 (en) * 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
EP1667955A2 (en) 2003-07-28 2006-06-14 SmithKline Beecham Corporation Cycloalkylidene compounds as modulators of the estrogen receptor
US7196119B2 (en) * 2003-10-21 2007-03-27 The Regents Of The University Of California Development of new selective estrogen receptor modulators
WO2006024689A1 (en) * 2004-09-03 2006-03-09 Hormos Medical Ltd. Use of a selective estrogen receptor modulator for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency
WO2007099410A2 (en) * 2005-11-09 2007-09-07 Hormos Medical Ltd. Formulations of fispemifene
US20080319078A1 (en) * 2005-11-22 2008-12-25 Subba Reddy Katamreddy Triphenylethylene Compounds Useful as Selective Estrogen Receptor Modulators
CN101437395A (zh) * 2005-11-22 2009-05-20 史密丝克莱恩比彻姆公司 化合物
US20080255089A1 (en) * 2005-11-22 2008-10-16 Smithkline Beecham Corporation Triphenylethylene Compounds Useful as Selective Estrogen Receptor Modulators
CN101484000A (zh) * 2005-11-22 2009-07-15 史密丝克莱恩比彻姆公司 化合物
MX2008014825A (es) 2006-05-22 2008-12-01 Hormos Medical Ltd Moduladores selectivos del receptor de estrogeno o inhibidores de aromatasa para tratar prostatitis cronica no bacteriana.
PL2121553T3 (pl) 2007-02-14 2012-11-30 Hormos Medical Ltd Sposób wytwarzania cennych terapeutycznie pochodnych trifenylobutenu
WO2008099060A2 (en) 2007-02-14 2008-08-21 Hormos Medical Ltd Methods for the preparation of fispemifene from ospemifene
WO2008157335A2 (en) * 2007-06-13 2008-12-24 Quatrx Pharmaceuticals Company Methods for the treatment of erectile dysfunction using fispemifene
BRPI0818637A2 (pt) 2007-10-16 2015-04-07 Repros Therapeutics Inc Métodos de tratamento de sintoma da síndrome metabólica, de glicose em jejum prejudicada, da síndrome metabólica e de redução de níveis de glicose em, jejum em sujeito com hipogonadismo hipogonadotrófico secundário ou idiopático
WO2009120999A2 (en) * 2008-03-28 2009-10-01 Olema Pharmaceuticals, Inc. Use of an endoxifen prodrug for treatment of breast cancer
US8318667B2 (en) 2009-02-25 2012-11-27 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
EP2526080B1 (en) * 2010-01-19 2014-03-26 Cambrex Karlskoga AB New processes for producing benzophenone derivatives
CN102906156B (zh) * 2010-05-20 2015-09-09 巴斯夫欧洲公司 三(2-羟基苯基)甲烷的衍生物及其制备和用途
DE102010027016A1 (de) 2010-07-09 2012-01-12 Universitätsklinikum Jena Steroid-Styrylfarbstoff-Konjugate zur Simulation und direkten lichtoptischen Detektion des Verhaltens von Steroiden im lebenden biologischen Gewebe und in Gegenwart von steroidbindenden Proteinen
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
KR101308258B1 (ko) * 2010-10-15 2013-09-13 씨제이제일제당 (주) 엔독시펜의 신규한 제조 방법
WO2013097773A1 (en) * 2011-12-30 2013-07-04 Centaurus Biopharma Co., Ltd. Novel arylalkene derivatives and use thereof as selective estrogen receptor modulators
CN102532073A (zh) * 2011-12-30 2012-07-04 北京赛林泰医药技术有限公司 作为选择性雌激素受体调节剂的乙烯衍生物
CN102584687A (zh) * 2011-12-30 2012-07-18 北京赛林泰医药技术有限公司 作为选择性雌激素受体调节剂的乙烯衍生物
JP2015508825A (ja) 2012-02-29 2015-03-23 レプロス セラピューティクス インコーポレイティド アンドロゲン欠乏症を治療するための併用療法
US9499538B2 (en) 2012-03-20 2016-11-22 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
US9321712B2 (en) 2012-10-19 2016-04-26 Fermion Oy Process for the preparation of ospemifene
WO2014060640A1 (en) 2012-10-19 2014-04-24 Fermion Oy A process for the preparation of ospemifene
WO2014141292A2 (en) * 2013-03-04 2014-09-18 Intas Pharmaceuticals Limited Endoxifen citrate polymorph and process for preparing the same
US9744177B2 (en) * 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
CA2962186A1 (en) * 2014-09-16 2016-03-24 Shionogi & Co., Ltd. Method for producing triphenylbutene derivative
CA2971216A1 (en) * 2014-12-23 2016-06-30 The Regents Of The University Of California Methods for immunomodulation of cancer and infectious disease therapy
EP3373967B9 (en) 2015-11-10 2023-10-04 Paracrine Therapeutics AB Treatment of er-negative breast cancer with an pdgf-cc inhibitor and an anti estrogen
MX2018010466A (es) 2016-03-15 2019-01-14 Shionogi & Co Metodo de produccion para derivados de fenoxietanol.
KR101819639B1 (ko) * 2016-06-27 2018-01-17 주식회사 케미메디 신규한 아릴에텐 유도체 및 이를 유효성분으로 함유하는 약제학적 조성물
CN109563054B (zh) * 2016-06-27 2022-08-05 大邱庆北尖端医疗产业振兴财团 新型芳基乙烯衍生物以及以该新型芳基乙烯为有效成分的药物组合物
KR102052133B1 (ko) * 2017-08-10 2019-12-05 고려대학교 산학협력단 당 부가된 오스페미펜, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물
WO2019103989A1 (en) * 2017-11-22 2019-05-31 Temple University-Of The Commonwealth System Of Higher Education Novel functionalized n,n-dialkylamino phenyl ethers and their method of use
SG11202105256QA (en) 2018-11-21 2021-06-29 Accutar Biotechnology Inc Novel compounds having estrogen receptor alpha degradation activity and uses thereof
JP2023508357A (ja) 2019-12-23 2023-03-02 アキュター バイオテクノロジー インコーポレイテッド エストロゲン受容体分解剤とサイクリン依存性キナーゼ阻害剤との癌治療用組み合わせ
US12496309B2 (en) 2020-06-22 2025-12-16 Novmetapharma Co., Ltd. Method for treatment of pancreatitis
US11413270B2 (en) * 2020-06-22 2022-08-16 Novmetapharma Co., Ltd. Method for the treatment of pancreatitis
CN116113409B (zh) 2020-08-04 2026-02-03 诺麦塔制药有限公司 细胞因子释放综合征的治疗方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637389A (https=) 1962-09-13
GB2042519B (en) * 1979-01-17 1983-03-23 Biorex Laboratories Ltd 1,1,2-triphenylethane and -ehylene derivatives
US4656187A (en) 1981-08-03 1987-04-07 Eli Lilly And Company Treatment of mammary cancer
FI67538C (fi) * 1982-05-27 1985-04-10 Farmos Oy Foerfarande foer framstaellning av (z)-1,2-difenyl-1-(4-(2-(n n-dimetylamino)etoxi)fenyl)-1-buten
GB2126576B (en) * 1982-06-25 1985-06-19 Farmos Group Limited Alkane and alkene derivatives
FI77839C (fi) * 1982-05-27 1989-05-10 Farmos Oy Foerfarande foer framstaellning av nya terapeutiskt effektiva trifenylalkan- och alkenderivat.
US5491173A (en) 1982-06-25 1996-02-13 Orion-Yhtyma Oy Tri-phenyl alkene derivatives and their preparation and use
US4729999A (en) 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
DE3762617D1 (de) * 1986-09-11 1990-06-13 Nat Res Dev Tamoxifenderivate.
US5189212A (en) 1990-09-07 1993-02-23 University Of Georgia Research Foundation, Inc. Triarylethylene carboxylic acids with estrogenic activity
US5219548A (en) 1990-10-01 1993-06-15 Board Of Regents, The University Of Texas System High affinity halogenated-tamoxifen derivatives and uses thereof
EP0551434B1 (en) 1990-10-01 1995-11-15 The Board Of Regents, The University Of Texas System High affinity tamoxifen derivatives and uses thereof
US6096874A (en) 1990-10-01 2000-08-01 Board Of Regents, The University Of Texas System High affinity tamoxifen derivatives
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
US5196435A (en) 1991-11-21 1993-03-23 Eli Lilly And Company Melatonin derivatives and combinations with antiestrogen compounds for treating mammalian breast carcinoma
GB9207437D0 (en) 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
US5446203A (en) 1992-08-25 1995-08-29 New York University Synthesis of haloenones and aryl or alkyl substituted enones or alkenes
DE4335876A1 (de) 1993-10-17 1995-04-20 Schering Ag Kombination von Progesteronantagonisten und Antiöstrogenen mit partialer agonistischer Wirkung für die Hormonsubstitutions-Therapie für peri- und postmenopausale Frauen
US5650425A (en) 1994-04-04 1997-07-22 Pharmos Corporation Permanently ionic derivatives of steroid hormones and their antagonists
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5604248A (en) 1994-05-05 1997-02-18 Eli Lilly And Company Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs
US5470883A (en) 1994-05-23 1995-11-28 Stromberg; Brent V. Method of treating peripheral vasoconstriction with tamoxifen citrate
US5441986A (en) 1994-07-19 1995-08-15 Pfizer Inc. Estrogen agonists as remedies for prostate and cardiovascular diseases
GB9418067D0 (en) * 1994-09-07 1994-10-26 Orion Yhtymae Oy Triphenylethylenes for the prevention and treatment of osteoporosis
US5629425A (en) * 1994-09-19 1997-05-13 Eli Lilly And Company Haloalkyl hemisolvates of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-piperidinoethoxy)-benzoyl]benzo[b]thiophene
US5658931A (en) 1994-09-20 1997-08-19 Eli Lilly And Company Method for inhibiting mammalian breast carcinoma with tamoxifen, and analogs thereof, and certain naphthyl compounds
CN1167437A (zh) 1994-11-29 1997-12-10 赫彻斯特马里恩鲁斯公司 用三芳基-乙烯衍生物治疗和预防骨质疏松的方法
US5821254A (en) 1995-02-17 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Uses of 9-cis-retinoic acids and derivatives thereof alone or in combination with antineoplastic agents in the prevention or treatment of cancer
GB9509572D0 (en) * 1995-05-11 1995-07-05 Cancer Res Campaign Tech Cancer therapy
DE19526146A1 (de) 1995-07-07 1997-01-09 Schering Ag Triphenylethylene, Verfahren zu deren Herstellung, diese Triphenylethylene enthaltene pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
GB9604577D0 (en) 1996-03-04 1996-05-01 Orion Yhtymae Oy Serum cholesterol lowering agent
GB9803521D0 (en) * 1998-02-19 1998-04-15 Orion Yhtymo Oy New compounds and pharmaceutical compositions thereof
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
TW593256B (en) * 1999-11-16 2004-06-21 Hormos Medical Oy Ltd Triphenylalkene derivatives and their use as selective estrogen receptor modulators

Also Published As

Publication number Publication date
US6576645B1 (en) 2003-06-10
AU1150301A (en) 2001-05-30
MXPA02002154A (es) 2002-09-18
ES2253268T3 (es) 2006-06-01
HUP0204029A2 (hu) 2003-03-28
EP1235776A1 (en) 2002-09-04
BG65853B1 (bg) 2010-03-31
NO20093175L (no) 2002-05-15
EP1235776B1 (en) 2006-02-08
KR20020072278A (ko) 2002-09-14
US20030225130A1 (en) 2003-12-04
HRP20020223C1 (en) 2012-12-31
NO328010B1 (no) 2009-11-09
TW593256B (en) 2004-06-21
IL148198A0 (en) 2002-09-12
NZ518542A (en) 2003-06-30
EE05126B1 (et) 2009-02-16
US6875775B2 (en) 2005-04-05
IL148198A (en) 2009-05-04
UA76409C2 (uk) 2006-08-15
CZ304738B6 (cs) 2014-09-17
PT1235776E (pt) 2006-05-31
SK287752B6 (sk) 2011-08-04
CN1399622A (zh) 2003-02-26
HU228512B1 (en) 2013-03-28
BR0014901A (pt) 2002-06-11
PL355708A1 (en) 2004-05-17
KR100877487B1 (ko) 2009-01-12
HUP0204029A3 (en) 2005-04-28
ZA200201433B (en) 2003-04-30
CA2390116C (en) 2009-04-07
PL201512B1 (pl) 2009-04-30
AU778296B2 (en) 2004-11-25
CN1861555A (zh) 2006-11-15
CA2390116A1 (en) 2001-05-25
JP2003514786A (ja) 2003-04-22
JP4202647B2 (ja) 2008-12-24
NO332328B1 (no) 2012-08-27
DK1235776T3 (da) 2006-04-10
SK6712002A3 (en) 2002-09-10
NO20022317D0 (no) 2002-05-15
EE200200190A (et) 2003-06-16
CN100441556C (zh) 2008-12-10
HRP20020223A2 (en) 2005-02-28
CZ20021623A3 (cs) 2002-08-14
DE60025938D1 (de) 2006-04-20
DE60025938T2 (de) 2006-08-10
ATE317378T1 (de) 2006-02-15
HK1051850A1 (en) 2003-08-22
BRPI0014901B8 (pt) 2021-05-25
NO20022317L (no) 2002-05-15
HRPK20020223B3 (en) 2006-11-30
BG106413A (bg) 2002-11-29
RU2247715C2 (ru) 2005-03-10
BRPI0014901B1 (pt) 2016-08-02
KR20080015924A (ko) 2008-02-20
WO2001036360A1 (en) 2001-05-25

Similar Documents

Publication Publication Date Title
CN1263720C (zh) 三苯基烯烃衍生物和它们作为选择性雌激素受体调制剂的用途
CN1242983C (zh) 苯氧基乙酸衍生物和含有该衍生物的医药组合物
CN1147459C (zh) 钙受体活性化合物
CN1224614C (zh) 吲哚满－2－酮衍生物、其制备方法及其作为催产素受体配体的应用
CN1291196A (zh) 新的抗雌激素甾族化合物、有关的药学组合物和使用方法
CN1251569A (zh) 新颖化合物,其用途及制法
CN1221401A (zh) 钙代谢化合物
CN1183098C (zh) 3-氨基-3-芳基丙-1-醇衍生物及其制备和应用
CN1419534A (zh) 治疗用的二苯基醚化合物
CN1469743A (zh) 雌激素受体调节剂
CN1281585C (zh) 具有稠环基团的环二胺化合物
HK1051850B (en) Triphenylalkene derivatives and their use as selective estrogen receptor modulators
CN1083055A (zh) 药剂
CN1703393A (zh) 螺环化合物、含有该化合物的药用组合物和该化合物的中间体
CN1751019A (zh) 氨基醇衍生物、含有所述氨基醇衍生物的药物组合物及其应用
CN1907949A (zh) 钙受体活性化合物
CN1387518A (zh) 杂环取代的二苯基白三烯拮抗剂
HK1054921A (en) Compound having hydroxycarbonyl-halogenoalkyl side chain

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CI01 Publication of corrected invention patent application

Correction item: Fifth, sixth inventor

Correct: M.-L. Sidwald|A. Carapindas|L.. Cangas|R. Lahmingta|P. Haier Corning|K. Weinening

False: M.-L. Sidwald|A. Carapindas|L.. Cangas|K. Wernerin

Number: 9

Page: 137

Volume: 19

CI02 Correction of invention patent application

Correction item: Fifth, sixth inventor

Correct: M.-L. Sidwald|A. Carapindas|L.. Cangas|R. Lahmingta|P. Haier Corning|K. Weinening

False: M.-L. Sidwald|A. Carapindas|L.. Cangas|K. Wernerin

Number: 9

Page: The title page

Volume: 19

COR Change of bibliographic data

Free format text: CORRECT: THE FIFTH, THE SIXTH INVENTOR; FROM: M.-L.THEDELVA A.CARAPUDAS L.CANGAS K. NING VENERAND TO: M.-L.THEDELVA A.CARAPUDAS L.CANGAS R.LAMINE TAO STAFFAN P.HAIR CONING K. NING VENERAND

ERR Gazette correction

Free format text: CORRECT: THE FIFTH, THE SIXTH INVENTOR; FROM: M.-L.THEDELVA A.CARAPUDAS L.CANGAS K. NING VENERAND TO: M.-L.THEDELVA A.CARAPUDAS L.CANGAS R.LAMINE TAO STAFFAN P.HAIR CONING K. NING VENERAND

C14 Grant of patent or utility model
GR01 Patent grant
C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20161228

Address after: Turku

Patentee after: Valorum multi Pharmaceutical Co. Ltd.

Address before: Turku

Patentee before: Hormos Medical Ltd.

CX01 Expiry of patent term

Granted publication date: 20060712

CX01 Expiry of patent term